Payment overview · 2025
General Payments
$1,213.83
62 reported records · 18 companies
Healthcare provider profile · identity verified
Michael Russo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARRERO, LA · NPI 1194887125
Verified facts
What the public records show
CMS Open Payments records show Michael Russo, M.D. received $1,213.83 in general payments during 2025 across 62 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.54 | 17.4% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $169.31 | 13.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.45 | 13.0% | 11 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $144.53 | 11.9% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $110.54 | 9.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.92 | 6.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.72 | 4.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.72 | 3.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $41.42 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.27 | 3.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.34 | 2.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.03 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.25 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.36 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.82 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.46 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.16 | 1.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.99 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,212.63 | 61 |
| Education | $1.20 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $161.34 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $147.91 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $110.54 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $109.83 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $107.32 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.12 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $80.92 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $61.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $41.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $37.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 323 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
323 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
323 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 742 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 566 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 71 |
| Furosemide | Furosemide | 326 | 70 |
| Eliquis | Apixaban | 323 | 50 |
| Gabapentin | Gabapentin | 290 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 50 |
| Lisinopril | Lisinopril | 256 | 60 |
| Trazodone Hcl | Trazodone Hcl | 238 | 52 |
| Metformin Hcl | Metformin Hcl | 235 | 53 |
| Tramadol Hcl | Tramadol Hcl | 231 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 31 |
| Potassium Chloride | Potassium Chloride | 178 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 36 |
| Januvia | Sitagliptin Phosphate | 167 | 12 |
| Omeprazole | Omeprazole | 165 | 36 |
| Clonidine | Clonidine | 160 | 33 |
| Carvedilol | Carvedilol | 159 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 42 |
| Levetiracetam | Levetiracetam | 147 | 29 |
| Clonidine Hcl | Clonidine Hcl | 141 | 27 |
| Famotidine | Famotidine | 139 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 26 |
| Donepezil Hcl | Donepezil Hcl | 131 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 131 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 28 |
| Sertraline Hcl | Sertraline Hcl | 126 | 22 |
| Losartan Potassium | Losartan Potassium | 124 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 44 |
| Ozempic | Semaglutide | 114 | 28 |
| Clonazepam | Clonazepam | 113 | 18 |
| Spironolactone | Spironolactone | 110 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 39 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 106 | 32 |
| Farxiga | Dapagliflozin Propanediol | 103 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 26 |
| Prednisone | Prednisone | 98 | 43 |
| Memantine Hcl | Memantine Hcl | 97 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 18 |
| Tradjenta | Linagliptin | 93 | 11 |
| Xarelto | Rivaroxaban | 92 | 16 |
| Mounjaro | Tirzepatide | 90 | 13 |
| Allopurinol | Allopurinol | 89 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 16 |
| Alprazolam | Alprazolam | 86 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 86 | suppressed |
| Trulicity | Dulaglutide | 86 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 52 |
| Mirtazapine | Mirtazapine | 84 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 21 |
| Ibuprofen | Ibuprofen | 81 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 21 |
| Montelukast Sodium | Montelukast Sodium | 78 | 17 |
| Topiramate | Topiramate | 77 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 13 |
| Lactulose | Lactulose | 76 | 18 |
| Lorazepam | Lorazepam | 72 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | suppressed |
| Olanzapine | Olanzapine | 64 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 63 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 15 |
| Glimepiride | Glimepiride | 61 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 56 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 55 | 12 |
| Buspirone Hcl | Buspirone Hcl | 54 | 12 |
| Gemtesa | Vibegron | 54 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 54 | 12 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 11 |
| Linzess | Linaclotide | 50 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 47 | 13 |
| Kerendia | Finerenone | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 30 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Lacosamide | Lacosamide | 42 | suppressed |
| Methadone Hcl | Methadone Hcl | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 12 |
| Megestrol Acetate | Megestrol Acetate | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 27 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 13 |
| Naproxen | Naproxen | 30 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 30 | suppressed |
| Azithromycin | Azithromycin | 28 | 22 |
| Ramipril | Ramipril | 28 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Nateglinide | Nateglinide | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 15 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Tivicay | Dolutegravir Sodium | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Nayzilam | Midazolam | 17 | 11 |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Paricalcitol | Paricalcitol | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,213.83 · 62 records | AstraZeneca Pharmaceuticals LP | AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, Kerendia, Korlym, NURTEC ODT, Ozempic, PONVORY, QULIPTA, REXULTI, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, ZENPEP, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error